Reuters exclusively reports Teva Pharm unlikely to reach deals to co-produce vaccines

Reuters exclusively reported that Israel’s Teva Pharmaceutical Industries is not likely to reach deals with COVID vaccine makers to co-produce the vaccines although discussions are still ongoing. Chief executive Kare Schultz told Reuters that Teva — the world’s largest generic drugmaker — offered to co-produce the vaccines in both Israel and Europe, where the company has capacity, to help with global supply. “But we’ve not been able to reach a firm agreement with any company,” he said.

Article Tags
Topics of Interest: Health
Type: Reuters Best
Sectors: Pharmaceuticals & Healthcare
Regions: Middle East
Countries: Israel
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Media Types: Text
Customer Impact: Important Regional Story
Sign up for email updates

Sign up for email updates